RedHill Biopharma (RDHL) announced that the Company received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market dated April 15, notifying the Company that ...

RedHill Biopharma (RDHL) announced the new publication of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an article entitled “Opaganib Promotes Weight Loss ...

Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial ...

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the ...

We came across a bullish thesis on Mereo BioPharma Group plc (MREO) on Substack by Jake LaMotta. In this article, we will summarize the bulls’ thesis on MREO. Mereo BioPharma Group plc (MREO ...

Market disruptor potential: The rapidly growing global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 [1] – largely driven by GLP-1 inhibitors like Novo ...

New Delhi: The initial public offerings (IPOs) in the biopharmaceutical sector surged 68.4 per cent to reach $8.52 billion globally in 2024, according to a new report. The sector saw an upturn in ...

GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with ...

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the ...